Related Experiment Video
Updated: Mar 30, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus
E Aragon1, L P Resontoc1, Y H Chan2
1Shaw-NKF-NUH Children's Kidney Centre, Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore.
Insights
This study shows that a multi-targeted treatment protocol for children with severe lupus nephritis (LN) leads to long-term remission and kidney preservation. The treatment demonstrated good patient survival and a favorable safety profile over nearly a decade of follow-up.
Area of Science:
- Pediatric Nephrology
- Immunology
- Rheumatology
Background:
- Severe proliferative lupus nephritis (LN) in children poses significant risks for long-term kidney damage.
- Previous one-year outcomes indicated efficacy of a multi-targeted induction protocol.
- Long-term data are crucial for evaluating sustained remission and renal preservation in pediatric LN.
Purpose of the Study:
- To assess the long-term renal outcomes in children with severe proliferative LN treated with a specific multi-targeted protocol.
- To evaluate patient and renal survival, relapse-free survival, and event-free survival.
- To analyze changes in clinical and laboratory parameters over an extended follow-up period.
Main Methods:
- Retrospective analysis of 16 children with severe proliferative LN.
- Treatment protocol included intravenous pulse methylprednisolone (MP), mycophenolate mofetil (MMF), and cyclosporine (CSA).
- Long-term follow-up (median 9.2 years) assessed complete renal remission, survival rates, and clinical/laboratory markers.
Main Results:
- All patients achieved complete renal remission within 24 months (median 8.7 months).
- Significant improvements observed in SLEDAI scores, serum C3 levels, eGFR, and urine protein levels.
- Cumulative ten-year renal relapse-free survival was 73.3%; 71.4% probability of avoiding hospitalization at ten years.
Conclusions:
- The multi-targeted induction and maintenance therapy protocol is effective for long-term renal preservation in Asian children with severe proliferative LN.
- The protocol demonstrates good patient survival and a favorable safety profile.
- Sustained remission and improved renal function markers indicate the protocol's long-term benefits.
Abstract:
We have previously reported the one-year outcomes of 16 children with severe proliferative lupus nephritis (LN) who were treated using a multi-targeted induction protocol based on intravenous (IV) pulse methylprednisolone (MP), mycophenolate mofetil (MMF) and cyclosporine (CSA). This study examined the long-term renal outcomes of these 16 children, followed up for a median duration of 9.2 years (range 5.8-14.2 years). Primary treatment outcome was complete renal remission. Secondary outcomes included patient and renal survival as well as relapse-free and event-free survival. All patients achieved complete renal remission within 24 months (median 8.7 months, range 4.0-24.0 months). Comparing clinical and laboratory parameters at induction and last follow-up, respectively, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score (25.4 ± 8.7 vs. 0.4 ± 0.8), serum complement C3 (47 ± 21 vs. 107 ± 27 mg/dL), estimated glomerular filtration rate (eGFR) (72 ± 57 vs. 109.7 ± 43 ml/min/1.73 m2) and urine protein (6.97 ± 7.09 vs. 0.2 ± 0.02 g/day/1.73 m2) improved significantly (p < 0.05). Kaplan-Meier survival analysis showed a cumulative ten-year renal relapse-free survival of 73.3% when considering relapses with severe proteinuria >1 g/day/1.73 m2. Cumulative probability that hospitalization would not be required was 93.8% at one year, and 71.4% at ten years. Our multi-targeted protocol for induction and maintenance therapy in Asian children with severe proliferative LN resulted in good long-term patient survival and renal preservation, with a good safety profile.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Pharmacokinetics in Pediatric Patients: Drug Excretion
Kidney Transplant III: Nursing Management
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

